Indian companies interested in buying Sanofi's European generics business

Indian drugmakers Aurobindo, Zydus Cadila, Torrent Pharmaceuticals and Intas Pharmaceuticals are among suitors vying for Sanofi’s (Euronext: SAN) attention, as the French drugmaker looks to offload its European generics business.

The deal could be worth between $1.5 and $2 billion, local press reports, for which price the winning bidder will acquire a portfolio of acute, chronic and oncology products.

Sanofi, which runs its generics business under its 2008 Czech acquisition Zentiva, has given a mandate to JPMorgan, Morgan Stanley and Rothschild to run the sale process.